Evidence map›Paper›PMID 34841362›Full record

ArticleCurrent research in microbial sciences2021

Intranasal inoculation with

Thibaut Naninck, Vanessa Contreras, Loïc Coutte, Sébastien Langlois, Aurélie Hébert-Ribon, Magali Pelletier, Nathalie Reveneau, Camille Locht, Catherine Chapon, Roger Le Grand

Open access · goldAbstract read
In one paragraph

Article in Current research in microbial sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Clinical microbiology reviews · 2023
    Review
  5. Generating enhanced mucosal immunity againstFrontiers in immunology · 2023
    Article
  6. Article
  7. Non-primate animal models for pertussis: back to the drawing board?Applied microbiology and biotechnology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 1 country.

Thibaut NaninckUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.
Vanessa ContrerasUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.
Loïc CoutteUniv. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR8204 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France.
Sébastien LangloisUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.
Aurélie Hébert-RibonSanofi-Pasteur MSD, Marcy l'Etoile, France.
Magali PelletierSanofi-Pasteur MSD, Marcy l'Etoile, France.
Nathalie ReveneauSanofi-Pasteur MSD, Marcy l'Etoile, France.
Camille LochtUniv. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR8204 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France.
Catherine ChaponUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.
Roger Le GrandUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.
Sanofi (France) · FRCEA Paris-Saclay · FRCentre Hospitalier Universitaire de Lille · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRInfectious Disease Models and Innovative Therapies · FRInserm · FRInstitut Pasteur de Lille · FRUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe resurgence of whooping cough in many countries highlights the crucial need for a better understanding of the pathogenesis of respiratory infection by

methodsYoung baboons were intranasally exposed to the B1917 clinical isolate, representative of circulating strains in Europe, or its green-fluorescent protein expressing derivative. Animals were followed for pertussis symptoms and bacterial colonization and by

resultsSeroconversion and bacterial colonization of both the nasopharynx and trachea was observed in baboons exposed to B. pertussis by the intranasal route only, and also in those animals challenged by both the intranasal and intra-tracheal routes together. However, baboons exposed solely by the intranasal route developed only mild clinical symptoms, with no paroxysmal cough. These animals were protected against re-infection by

conclusionsIntranasal exposure of baboons to

Indexed as

BaboonsNon-human primatesPertussisWhooping cough

Identifiers

PMID34841362
PMCPMC8610340
OpenAlexW3206296000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.